Gland Pharma stock lose 24% of its value in 3 days. What’s spooking investors?
Gland Pharma said revenue from its core markets of the US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal
